Vascular Solutions Stock Price, News & Analysis (NASDAQ:VASC)

$56.00 0.00 (0.00 %)
(As of 11/24/2017 02:27 AM ET)
Previous Close$56.00
Today's Range$55.95 - $56.00
52-Week Range$25.06 - $57.15
Volume1.21 million shs
Average Volume248,891 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Vascular Solutions (NASDAQ:VASC)

Vascular Solutions logoVascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.

Receive VASC News and Ratings via Email

Sign-up to receive the latest news and ratings for VASC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryHealth Care Supplies
SectorMedical Diagnostic & Testing Equipment
SymbolNASDAQ:VASC
CUSIP92231M10
Phone+1-763-6564300

Debt

Debt-to-Equity RatioN/A
Current Ratio6.37%
Quick Ratio4.66%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.69
Net IncomeN/A
Net Margins13.02%
Return on Equity15.78%
Return on Assets14.30%

Miscellaneous

Employees568
Outstanding Shares17,570,000

Frequently Asked Questions for Vascular Solutions (NASDAQ:VASC)

What is Vascular Solutions' stock symbol?

Vascular Solutions trades on the NASDAQ under the ticker symbol "VASC."

How were Vascular Solutions' earnings last quarter?

Vascular Solutions, Inc. (NASDAQ:VASC) announced its quarterly earnings results on Monday, July, 25th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.30 by $0.03. The medical device company earned $41.20 million during the quarter, compared to the consensus estimate of $41.40 million. Vascular Solutions had a return on equity of 15.78% and a net margin of 13.02%. Vascular Solutions's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 earnings per share. View Vascular Solutions' Earnings History.

Who are some of Vascular Solutions' key competitors?

How do I buy Vascular Solutions stock?

Shares of Vascular Solutions can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Solutions' stock price today?

One share of Vascular Solutions stock can currently be purchased for approximately $56.00.

How can I contact Vascular Solutions?

Vascular Solutions' mailing address is 6464 Sycamore Ct N, MAPLE GROVE, MN 55369-6032, United States. The medical device company can be reached via phone at +1-763-6564300.


MarketBeat Community Rating for Vascular Solutions (VASC)

Community Ranking:  2.9 out of 5 (star star star)
Outperform Votes:  144 (Thanks for Voting!)
Underperform Votes:  101 (Thanks for Voting!)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about Vascular Solutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Vascular Solutions (NASDAQ:VASC)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.172.172.17
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.75$51.75$51.75$51.75
Price Target Upside: 7.59% downside7.59% downside7.59% downside7.59% downside

Consensus Price Target History for Vascular Solutions (NASDAQ:VASC)

Price Target History for Vascular Solutions (NASDAQ:VASC)

Analysts' Ratings History for Vascular Solutions (NASDAQ:VASC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/5/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/5/2016Canaccord GenuityDowngradeBuy -> HoldN/AView Rating Details
12/2/2016Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
12/2/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
7/12/2016SidotiDowngradeBuy -> Neutral$47.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Vascular Solutions (NASDAQ:VASC)

Earnings by Quarter for Vascular Solutions (NASDAQ:VASC)

Earnings History by Quarter for Vascular Solutions (NASDAQ VASC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2016Q3$0.30$0.31$41.60 million$41.77 millionViewListenView Earnings Details
7/25/2016Q216$0.30$0.33$41.40 million$41.20 millionViewListenView Earnings Details
4/25/2016Q116$0.23$0.25$38.37 million$39.00 millionViewListenView Earnings Details
1/21/2016Q415$0.27$0.33$37.53 million$38.09 millionViewListenView Earnings Details
10/20/2015Q315$0.25$0.27$36.41 million$37.00 millionViewListenView Earnings Details
7/21/2015Q215$0.25$0.29$35.59 million$37.60 millionViewListenView Earnings Details
4/21/2015Q115$0.18$0.21$33.38 million$34.61 millionViewN/AView Earnings Details
2/3/2015Q414$0.18$0.23$32.82 million$33.60 millionViewN/AView Earnings Details
10/21/2014Q314$0.20$0.15$31.10 million$31.90 millionViewListenView Earnings Details
7/22/2014Q214$0.18$0.20$30.43 million$30.70 millionViewN/AView Earnings Details
4/22/2014Q114$0.18$0.16$29.91 million$29.91 millionViewListenView Earnings Details
2/4/2014Q413$0.19$0.22$28.61 million$29.10 millionViewListenView Earnings Details
10/22/2013Q313$0.07$0.19$27.10 million$28.01 millionViewListenView Earnings Details
7/23/2013Q2 2013$0.17$0.17$27.00 million$27.40 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.15$0.16$26.51 million$26.10 millionViewListenView Earnings Details
2/5/2013Q4 2012$0.17$0.18$25.59 million$25.30 millionViewListenView Earnings Details
10/18/2012$0.15$0.16ViewN/AView Earnings Details
7/24/2012$0.13$0.15ViewN/AView Earnings Details
2/1/2012$0.13$0.13ViewN/AView Earnings Details
10/25/2011$0.17$0.10ViewN/AView Earnings Details
8/2/2011$0.12$0.13ViewN/AView Earnings Details
4/19/2011$0.10$0.10ViewN/AView Earnings Details
2/1/2011$0.12$0.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Solutions (NASDAQ:VASC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vascular Solutions (NASDAQ:VASC)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vascular Solutions (NASDAQ VASC)

Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 80.18%
Insider Trades by Quarter for Vascular Solutions (NASDAQ:VASC)
Institutional Ownership by Quarter for Vascular Solutions (NASDAQ:VASC)

Insider Trades by Quarter for Vascular Solutions (NASDAQ VASC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Chad KuglerVPSell1,849$55.70$102,989.30View SEC Filing  
7/27/2016Howard RootCEOSell40,000$45.11$1,804,400.00View SEC Filing  
7/27/2016William RutsteinVPSell10,011$46.26$463,108.86View SEC Filing  
5/24/2016Howard RootCEOSell34,418$39.05$1,344,022.90View SEC Filing  
5/13/2016James HennenCFOSell11,785$38.12$449,244.20View SEC Filing  
5/13/2016Martin J EmersonDirectorSell20,000$37.93$758,600.00View SEC Filing  
4/28/2016John L ErbDirectorSell10,000$35.58$355,800.00View SEC Filing  
4/27/2016Howard RootCEOSell15,582$36.07$562,042.74View SEC Filing  
4/27/2016Timothy SlaytonInsiderSell2,994$36.72$109,939.68View SEC Filing  
2/29/2016Charmaine SuttonVPSell14,325$30.13$431,612.25View SEC Filing  
11/19/2015Jorge SaucedoDirectorSell7,715$33.45$258,066.75View SEC Filing  
11/4/2015Richard NigonDirectorSell8,000$32.40$259,200.00View SEC Filing  
11/2/2015Howard RootCEOSell18,062$32.03$578,525.86View SEC Filing  
10/26/2015Carrie PowersVPSell5,412$32.77$177,351.24View SEC Filing  
8/20/2015Jorge SaucedoDirectorSell2,285$38.00$86,830.00View SEC Filing  
7/23/2015Timothy SlaytonInsiderSell1,587$38.61$61,274.07View SEC Filing  
5/28/2015Richard NigonDirectorSell6,000$32.68$196,080.00View SEC Filing  
5/4/2015Howard RootCEOSell25,000$32.62$815,500.00View SEC Filing  
4/27/2015Carrie PowersVPSell6,000$34.90$209,400.00View SEC Filing  
4/24/2015James HennenCFOSell4,792$35.66$170,882.72View SEC Filing  
2/10/2015William RutsteinVPSell10,814$26.91$291,004.74View SEC Filing  
2/5/2015James HennenCFOSell11,301$27.62$312,133.62View SEC Filing  
2/5/2015Jorge SaucedoDirectorSell10,000$27.36$273,600.00View SEC Filing  
11/26/2014Richard NigonDirectorBuy3,000$25.80$77,400.00View SEC Filing  
11/14/2014Richard W KrampDirectorBuy1,475$23.69$34,942.75View SEC Filing  
4/24/2014Timothy SlaytonInsiderSell1,390$23.15$32,178.50View SEC Filing  
2/27/2014James HennenCFOSell10,000$25.42$254,200.00View SEC Filing  
2/25/2014Howard RootCEOSell50,000$24.74$1,237,000.00View SEC Filing  
2/25/2014Richard NigonDirectorBuy1,000$25.66$25,660.00View SEC Filing  
2/14/2014Howard RootCEOSell25,000$25.13$628,250.00View SEC Filing  
2/11/2014Paul O'connellDirectorSell2,000$24.43$48,860.00View SEC Filing  
2/10/2014William RutsteinVPSell27,782$23.80$661,211.60View SEC Filing  
10/28/2013James HennenCFOSell10,000$19.72$197,200.00View SEC Filing  
10/25/2013Jorge SaucedoDirectorSell2,000$19.70$39,400.00View SEC Filing  
7/26/2013Charmaine SuttonVPSell7,538$16.15$121,738.70View SEC Filing  
7/25/2013Howard RootCEOSell21,580$16.10$347,438.00View SEC Filing  
7/25/2013Howard RootCEOSell21,580$16.10$347,438.00View SEC Filing  
7/25/2013Paul O'connellDirectorSell30,000$16.11$483,300.00View SEC Filing  
5/17/2013Paul O'connellDirectorSell10,000$16.05$160,500.00View SEC Filing  
5/1/2013Richard NigonDirectorBuy3,000$15.57$46,710.00View SEC Filing  
11/26/2012Susan ChristianVPSell7,648$14.41$110,207.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vascular Solutions (NASDAQ VASC)

Source:
DateHeadline
Urinary Catheters Market is Worth US$ 15830 Million By 2022Urinary Catheters Market is Worth US$ 15830 Million By 2022
www.marketwatch.com - November 16 at 5:08 AM
Teleflex (TFX) Q3 2017 Results - Earnings Call TranscriptTeleflex (TFX) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 3:40 PM
Vascular Solutions (VASC) & Myriad Genetics (MYGN) Critical SurveyVascular Solutions (VASC) & Myriad Genetics (MYGN) Critical Survey
www.americanbankingnews.com - September 9 at 2:12 AM
Analyzing VAREX IMAGING (VREX) and Vascular Solutions (VASC)Analyzing VAREX IMAGING (VREX) and Vascular Solutions (VASC)
www.americanbankingnews.com - September 5 at 10:22 AM
Head-To-Head Analysis: Vascular Solutions (VASC) vs. Myriad Genetics (MYGN)Head-To-Head Analysis: Vascular Solutions (VASC) vs. Myriad Genetics (MYGN)
www.americanbankingnews.com - September 3 at 4:02 AM
Financial Comparison: Myriad Genetics (MYGN) vs. Vascular Solutions (VASC)Financial Comparison: Myriad Genetics (MYGN) vs. Vascular Solutions (VASC)
www.americanbankingnews.com - August 30 at 4:26 PM
Reviewing Vascular Solutions (VASC) & Myriad Genetics (MYGN)Reviewing Vascular Solutions (VASC) & Myriad Genetics (MYGN)
www.americanbankingnews.com - August 29 at 8:06 PM
Comparing Vascular Solutions (VASC) and Cepheid (CPHD)Comparing Vascular Solutions (VASC) and Cepheid (CPHD)
www.americanbankingnews.com - August 27 at 12:28 AM
Head-To-Head Comparison: Vascular Solutions (VASC) and Varex Imaging (VREX)Head-To-Head Comparison: Vascular Solutions (VASC) and Varex Imaging (VREX)
www.americanbankingnews.com - August 25 at 4:30 PM
Financial Analysis: Varex Imaging (VREX) & Vascular Solutions (VASC)Financial Analysis: Varex Imaging (VREX) & Vascular Solutions (VASC)
www.americanbankingnews.com - August 18 at 6:14 PM
Financial Contrast: Cepheid (CPHD) & Vascular Solutions (NASDAQ:VASC)Financial Contrast: Cepheid (CPHD) & Vascular Solutions (NASDAQ:VASC)
www.americanbankingnews.com - August 10 at 3:02 PM
Teleflex (TFX) Q2 2017 Results - Earnings Call TranscriptTeleflex (TFX) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 9:37 AM
Vascular Solutions (VASC) versus Cepheid (CPHD) Head-To-Head ContrastVascular Solutions (VASC) versus Cepheid (CPHD) Head-To-Head Contrast
www.americanbankingnews.com - August 4 at 7:42 AM
Head to Head Survey: Vascular Solutions (VASC) & Sequenom (SQNM)Head to Head Survey: Vascular Solutions (VASC) & Sequenom (SQNM)
www.americanbankingnews.com - July 13 at 8:30 PM
Head to Head Survey: Oxford Immunotec Global PLC (OXFD) & Vascular Solutions (VASC)Head to Head Survey: Oxford Immunotec Global PLC (OXFD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 1 at 8:12 AM
BRIEF-Teleflexs (TFX) Vascular Solutions issues recall of venture cathetersBRIEF-Teleflex's (TFX) Vascular Solutions issues recall of venture catheters
www.reuters.com - June 22 at 7:31 PM
Teleflex’s (TFX) Vascular Solutions, Inc. Issues Recall of Venture ® CathetersTeleflex’s (TFX) Vascular Solutions, Inc. Issues Recall of Venture ® Catheters
www.businesswire.com - June 22 at 7:31 PM
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, ParisTeleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
www.zacks.com - May 16 at 8:24 AM
Sunshine Heart Hires Gordon Weber as Vice President, General CounselSunshine Heart Hires Gordon Weber as Vice President, General Counsel
globenewswire.com - May 16 at 8:24 AM
Teleflex Lifts 2017 Profit ViewTeleflex Lifts 2017 Profit View
www.nasdaq.com - May 4 at 9:49 AM
1:01 pm Index Changes Reminder: Progenics Pharmaceuticals (<a href="/q?s=pgnx" name="pgnx">PGNX</a>) replaced Calamos Asset (<a href="/q?s=clms" name="clms">CLMS</a>) in the S&P SmallCap 600 this morning; and Shutterfly (<a href="/q?s=sfly"1:01 pm Index Changes Reminder: Progenics Pharmaceuticals (PGNX) replaced Calamos Asset (CLMS) in the S&P SmallCap 600 this morning; and Shutterfly (
us.rd.yahoo.com - February 23 at 3:06 AM
VASCULAR SOLUTIONS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisitionVASCULAR SOLUTIONS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition
biz.yahoo.com - February 22 at 10:46 AM
VASCULAR SOLUTIONS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, FinanciVASCULAR SOLUTIONS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi
biz.yahoo.com - February 17 at 5:57 AM
Vascular Solutions CEO Howard Root stands to receive $8M in sale of companyVascular Solutions CEO Howard Root stands to receive $8M in sale of company
www.bizjournals.com - January 19 at 4:18 PM
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Shareholders To Contact The Firm For Additional ...INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - December 18 at 4:04 AM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Investors To Contact The Firm For Additional ...SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - December 14 at 8:19 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Vascular Solutions, Inc. to Teleflex Incorporated for $24 Per Share is Fair to ...INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Vascular Solutions, Inc. to Teleflex Incorporated for $24 Per Share is Fair to ...
www.businesswire.com - December 7 at 9:13 PM
Company News for December 05, 2016Company News for December 05, 2016
us.rd.yahoo.com - December 5 at 3:56 PM
Ryan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc.Ryan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc.
us.rd.yahoo.com - December 5 at 3:56 PM
VASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Teleflex IncorporatedVASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Teleflex Incorporated
us.rd.yahoo.com - December 5 at 3:56 PM
Medical device maker Teleflex to buy Vascular Solutions for $1 billionMedical device maker Teleflex to buy Vascular Solutions for $1 billion
www.foxnews.com - December 3 at 9:37 AM

Social Media

Financials

Chart

Vascular Solutions (NASDAQ VASC) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.